APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Human Papillomavirus Protein E7

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Human Papillomavirus Protein E7 Market Outlook and Growth Opportunities 2026

Report ID 173999980419 December 2025205 pages

Choose your research edition.

Industry ResearchHuman Papillomavirus Protein E7 Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Papillomavirus Protein E7 Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Human Papillomavirus Protein E7 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Papillomavirus Protein E7 Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Papillomavirus Protein E7 Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Human Papillomavirus Protein E7 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Human Papillomavirus Protein E7 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human Papillomavirus Protein E7 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Papillomavirus Protein E7 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Human Papillomavirus Protein E7 market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Human Papillomavirus Protein E7 market include VLPbio, Transgene SA, Touchlight Genetics Ltd, Selecta Biosciences Inc, MedImmune LLC, Inovio Pharmaceuticals Inc, Immunovaccine Inc, iBio Inc and Hookipa Biotech AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Human Papillomavirus Protein E7 market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Papillomavirus Protein E7 and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Papillomavirus Protein E7 sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Papillomavirus Protein E7 market size, projected growth trends, production technologies, key applications, and end-use industries.

Human Papillomavirus Protein E7 Segment by Company

VLPbio

Transgene SA

Touchlight Genetics Ltd

Selecta Biosciences Inc

MedImmune LLC

Inovio Pharmaceuticals Inc

Immunovaccine Inc

iBio Inc

Hookipa Biotech AG

Genexine Inc

Formune SL

Etubics Corp

Cancer Research Technology Ltd

BioNTech AG

Bioleaders Corp

Advaxis Inc

Abion Inc

Human Papillomavirus Protein E7 Segment by Type

CUE-201

CerviVax

CUE-101

BLSILSB-710c

Others

Human Papillomavirus Protein E7 Segment by Application

Rectal Cancer

Penile Cancer

Anal Cancer

Lung Cancer

Others

Human Papillomavirus Protein E7 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Human Papillomavirus Protein E7 status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Human Papillomavirus Protein E7 market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Human Papillomavirus Protein E7 significant trends, drivers, influence factors in global and regions.

6. To analyze Human Papillomavirus Protein E7 competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Papillomavirus Protein E7 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Papillomavirus Protein E7 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Papillomavirus Protein E7.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human Papillomavirus Protein E7 market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Papillomavirus Protein E7 industry.

Chapter 3: Detailed analysis of Human Papillomavirus Protein E7 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Human Papillomavirus Protein E7 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Human Papillomavirus Protein E7 in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Human Papillomavirus Protein E7 Industry Trends Table 2. Human Papillomavirus Protein E7 Industry Drivers Table 3. Human Papillomavirus Protein E7 Industry Opportunities and Challenges Table 4. Human Papillomavirus Protein E7 Industry Restraints Table 5. Global Human Papillomavirus Protein E7 Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Human Papillomavirus Protein E7 Revenue Share by Company (2021-2026) Table 7. Global Human Papillomavirus Protein E7 Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Human Papillomavirus Protein E7 Sales Volume Share by Company (2021-2026) Table 9. Global Human Papillomavirus Protein E7 Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Human Papillomavirus Protein E7 Company Ranking, (2024-2026) & (USD Million) Table 11. Global Human Papillomavirus Protein E7 Key Company Manufacturing Base & Headquarters Table 12. Global Human Papillomavirus Protein E7 Company, Product Type & Application Table 13. Global Human Papillomavirus Protein E7 Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Human Papillomavirus Protein E7 by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of CUE-201 Table 18. Significant Companies of CerviVax Table 19. Significant Companies of CUE-101 Table 20. Significant Companies of BLSILSB-710c Table 21. Significant Companies of Others Table 22. Global Human Papillomavirus Protein E7 Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Human Papillomavirus Protein E7 Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Human Papillomavirus Protein E7 Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Human Papillomavirus Protein E7 Sales Volume Share by Type (2021-2026) Table 26. Global Human Papillomavirus Protein E7 Sales Volume Share by Type (2027-2032) Table 27. Global Human Papillomavirus Protein E7 Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Human Papillomavirus Protein E7 Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Human Papillomavirus Protein E7 Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Human Papillomavirus Protein E7 Sales Value Share by Type (2021-2026) Table 31. Global Human Papillomavirus Protein E7 Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Rectal Cancer Table 33. Significant Companies of Penile Cancer Table 34. Significant Companies of Anal Cancer Table 35. Significant Companies of Lung Cancer Table 36. Significant Companies of Others Table 37. Global Human Papillomavirus Protein E7 Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Human Papillomavirus Protein E7 Sales Volume by Application (2021-2026) & (K Units) Table 39. Global Human Papillomavirus Protein E7 Sales Volume by Application (2027-2032) & (K Units) Table 40. Global Human Papillomavirus Protein E7 Sales Volume Share by Application (2021-2026) Table 41. Global Human Papillomavirus Protein E7 Sales Volume Share by Application (2027-2032) Table 42. Global Human Papillomavirus Protein E7 Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Human Papillomavirus Protein E7 Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Human Papillomavirus Protein E7 Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Human Papillomavirus Protein E7 Sales Value Share by Application (2021-2026) Table 46. Global Human Papillomavirus Protein E7 Sales Value Share by Application (2027-2032) Table 47. Global Human Papillomavirus Protein E7 Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 48. Global Human Papillomavirus Protein E7 Sales by Region (2021-2026) & (K Units) Table 49. Global Human Papillomavirus Protein E7 Sales Market Share by Region (2021-2026) Table 50. Global Human Papillomavirus Protein E7 Sales by Region (2027-2032) & (K Units) Table 51. Global Human Papillomavirus Protein E7 Sales Market Share by Region (2027-2032) Table 52. Global Human Papillomavirus Protein E7 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Human Papillomavirus Protein E7 Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Human Papillomavirus Protein E7 Sales Value Share by Region (2021-2026) Table 55. Global Human Papillomavirus Protein E7 Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Human Papillomavirus Protein E7 Sales Value Share by Region (2027-2032) Table 57. Global Human Papillomavirus Protein E7 Market Average Price (US$/Unit) by Region (2021-2026) Table 58. Global Human Papillomavirus Protein E7 Market Average Price (US$/Unit) by Region (2027-2032) Table 59. Global Human Papillomavirus Protein E7 Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. Global Human Papillomavirus Protein E7 Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Human Papillomavirus Protein E7 Sales by Country (2021-2026) & (K Units) Table 62. Global Human Papillomavirus Protein E7 Sales Market Share by Country (2021-2026) Table 63. Global Human Papillomavirus Protein E7 Sales by Country (2027-2032) & (K Units) Table 64. Global Human Papillomavirus Protein E7 Sales Market Share by Country (2027-2032) Table 65. Global Human Papillomavirus Protein E7 Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Human Papillomavirus Protein E7 Sales Value Market Share by Country (2021-2026) Table 67. Global Human Papillomavirus Protein E7 Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Human Papillomavirus Protein E7 Sales Value Market Share by Country (2027-2032) Table 69. VLPbio Company Information Table 70. VLPbio Business Overview Table 71. VLPbio Human Papillomavirus Protein E7 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. VLPbio Human Papillomavirus Protein E7 Product Portfolio Table 73. VLPbio Recent Development Table 74. Transgene SA Company Information Table 75. Transgene SA Business Overview Table 76. Transgene SA Human Papillomavirus Protein E7 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Transgene SA Human Papillomavirus Protein E7 Product Portfolio Table 78. Transgene SA Recent Development Table 79. Touchlight Genetics Ltd Company Information Table 80. Touchlight Genetics Ltd Business Overview Table 81. Touchlight Genetics Ltd Human Papillomavirus Protein E7 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Touchlight Genetics Ltd Human Papillomavirus Protein E7 Product Portfolio Table 83. Touchlight Genetics Ltd Recent Development Table 84. Selecta Biosciences Inc Company Information Table 85. Selecta Biosciences Inc Business Overview Table 86. Selecta Biosciences Inc Human Papillomavirus Protein E7 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Selecta Biosciences Inc Human Papillomavirus Protein E7 Product Portfolio Table 88. Selecta Biosciences Inc Recent Development Table 89. MedImmune LLC Company Information Table 90. MedImmune LLC Business Overview Table 91. MedImmune LLC Human Papillomavirus Protein E7 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. MedImmune LLC Human Papillomavirus Protein E7 Product Portfolio Table 93. MedImmune LLC Recent Development Table 94. Inovio Pharmaceuticals Inc Company Information Table 95. Inovio Pharmaceuticals Inc Business Overview Table 96. Inovio Pharmaceuticals Inc Human Papillomavirus Protein E7 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Inovio Pharmaceuticals Inc Human Papillomavirus Protein E7 Product Portfolio Table 98. Inovio Pharmaceuticals Inc Recent Development Table 99. Immunovaccine Inc Company Information Table 100. Immunovaccine Inc Business Overview Table 101. Immunovaccine Inc Human Papillomavirus Protein E7 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Immunovaccine Inc Human Papillomavirus Protein E7 Product Portfolio Table 103. Immunovaccine Inc Recent Development Table 104. iBio Inc Company Information Table 105. iBio Inc Business Overview Table 106. iBio Inc Human Papillomavirus Protein E7 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. iBio Inc Human Papillomavirus Protein E7 Product Portfolio Table 108. iBio Inc Recent Development Table 109. Hookipa Biotech AG Company Information Table 110. Hookipa Biotech AG Business Overview Table 111. Hookipa Biotech AG Human Papillomavirus Protein E7 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Hookipa Biotech AG Human Papillomavirus Protein E7 Product Portfolio Table 113. Hookipa Biotech AG Recent Development Table 114. Genexine Inc Company Information Table 115. Genexine Inc Business Overview Table 116. Genexine Inc Human Papillomavirus Protein E7 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Genexine Inc Human Papillomavirus Protein E7 Product Portfolio Table 118. Genexine Inc Recent Development Table 119. Formune SL Company Information Table 120. Formune SL Business Overview Table 121. Formune SL Human Papillomavirus Protein E7 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Formune SL Human Papillomavirus Protein E7 Product Portfolio Table 123. Formune SL Recent Development Table 124. Etubics Corp Company Information Table 125. Etubics Corp Business Overview Table 126. Etubics Corp Human Papillomavirus Protein E7 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Etubics Corp Human Papillomavirus Protein E7 Product Portfolio Table 128. Etubics Corp Recent Development Table 129. Cancer Research Technology Ltd Company Information Table 130. Cancer Research Technology Ltd Business Overview Table 131. Cancer Research Technology Ltd Human Papillomavirus Protein E7 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Cancer Research Technology Ltd Human Papillomavirus Protein E7 Product Portfolio Table 133. Cancer Research Technology Ltd Recent Development Table 134. BioNTech AG Company Information Table 135. BioNTech AG Business Overview Table 136. BioNTech AG Human Papillomavirus Protein E7 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. BioNTech AG Human Papillomavirus Protein E7 Product Portfolio Table 138. BioNTech AG Recent Development Table 139. Bioleaders Corp Company Information Table 140. Bioleaders Corp Business Overview Table 141. Bioleaders Corp Human Papillomavirus Protein E7 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Bioleaders Corp Human Papillomavirus Protein E7 Product Portfolio Table 143. Bioleaders Corp Recent Development Table 144. Advaxis Inc Company Information Table 145. Advaxis Inc Business Overview Table 146. Advaxis Inc Human Papillomavirus Protein E7 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Advaxis Inc Human Papillomavirus Protein E7 Product Portfolio Table 148. Advaxis Inc Recent Development Table 149. Abion Inc Company Information Table 150. Abion Inc Business Overview Table 151. Abion Inc Human Papillomavirus Protein E7 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Abion Inc Human Papillomavirus Protein E7 Product Portfolio Table 153. Abion Inc Recent Development Table 154. Key Raw Materials Table 155. Raw Materials Key Suppliers Table 156. Human Papillomavirus Protein E7 Distributors List Table 157. Human Papillomavirus Protein E7 Customers List Table 158. Research Programs/Design for This Report Table 159. Authors List of This Report Table 160. Secondary Sources Table 161. Primary Sources List of Figures Figure 1. Human Papillomavirus Protein E7 Product Image Figure 2. Global Human Papillomavirus Protein E7 Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Papillomavirus Protein E7 Sales Value (2021-2032) & (US$ Million) Figure 4. Global Human Papillomavirus Protein E7 Sales (2021-2032) & (K Units) Figure 5. Global Human Papillomavirus Protein E7 Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Human Papillomavirus Protein E7 Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. CUE-201 Image Figure 10. CerviVax Image Figure 11. CUE-101 Image Figure 12. BLSILSB-710c Image Figure 13. Others Image Figure 14. Global Human Papillomavirus Protein E7 Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Human Papillomavirus Protein E7 Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Human Papillomavirus Protein E7 Sales Volume Share by Type (2021-2032) Figure 17. Global Human Papillomavirus Protein E7 Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Human Papillomavirus Protein E7 Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Human Papillomavirus Protein E7 Sales Value Share by Type (2021-2032) Figure 20. Rectal Cancer Image Figure 21. Penile Cancer Image Figure 22. Anal Cancer Image Figure 23. Lung Cancer Image Figure 24. Others Image Figure 25. Global Human Papillomavirus Protein E7 Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Human Papillomavirus Protein E7 Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Human Papillomavirus Protein E7 Sales Volume Share by Application (2021-2032) Figure 28. Global Human Papillomavirus Protein E7 Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Human Papillomavirus Protein E7 Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Human Papillomavirus Protein E7 Sales Value Share by Application (2021-2032) Figure 31. Global Human Papillomavirus Protein E7 Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 32. Global Human Papillomavirus Protein E7 Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Human Papillomavirus Protein E7 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Human Papillomavirus Protein E7 Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Human Papillomavirus Protein E7 Sales Value (2021-2032) & (US$ Million) Figure 36. North America Human Papillomavirus Protein E7 Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Human Papillomavirus Protein E7 Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Human Papillomavirus Protein E7 Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Human Papillomavirus Protein E7 Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Human Papillomavirus Protein E7 Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Human Papillomavirus Protein E7 Sales Value (2021-2032) & (US$ Million) Figure 42. South America Human Papillomavirus Protein E7 Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Human Papillomavirus Protein E7 Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Human Papillomavirus Protein E7 Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Human Papillomavirus Protein E7 Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Human Papillomavirus Protein E7 Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • CUE-201
  • CerviVax
  • CUE-101
  • BLSILSB-710c
  • Others
Applications
  • Rectal Cancer
  • Penile Cancer
  • Anal Cancer
  • Lung Cancer
  • Others
Companies covered
  • VLPbio
  • Transgene SA
  • Touchlight Genetics Ltd
  • Selecta Biosciences Inc
  • MedImmune LLC
  • Inovio Pharmaceuticals Inc
  • Immunovaccine Inc
  • iBio Inc
  • Hookipa Biotech AG
  • Genexine Inc
  • Formune SL
  • Etubics Corp
  • Cancer Research Technology Ltd
  • BioNTech AG
  • Bioleaders Corp
  • Advaxis Inc
  • Abion Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Human Papillomavirus Protein E7 Sales Value (2021-2032)
  4. 1.2.2 Global Human Papillomavirus Protein E7 Sales Volume (2021-2032)
  5. 1.2.3 Global Human Papillomavirus Protein E7 Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Human Papillomavirus Protein E7 Market Dynamics
  1. 2.1 Human Papillomavirus Protein E7 Industry Trends
  2. 2.2 Human Papillomavirus Protein E7 Industry Drivers
  3. 2.3 Human Papillomavirus Protein E7 Industry Opportunities and Challenges
  4. 2.4 Human Papillomavirus Protein E7 Industry Restraints
3 Human Papillomavirus Protein E7 Market by Company
  1. 3.1 Global Human Papillomavirus Protein E7 Company Revenue Ranking in 2025
  2. 3.2 Global Human Papillomavirus Protein E7 Revenue by Company (2021-2026)
  3. 3.3 Global Human Papillomavirus Protein E7 Sales Volume by Company (2021-2026)
  4. 3.4 Global Human Papillomavirus Protein E7 Average Price by Company (2021-2026)
  5. 3.5 Global Human Papillomavirus Protein E7 Company Ranking (2024-2026)
  6. 3.6 Global Human Papillomavirus Protein E7 Company Manufacturing Base and Headquarters
  7. 3.7 Global Human Papillomavirus Protein E7 Company Product Type and Application
  8. 3.8 Global Human Papillomavirus Protein E7 Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Human Papillomavirus Protein E7 Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Human Papillomavirus Protein E7 Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Human Papillomavirus Protein E7 Market by Type
  1. 4.1 Human Papillomavirus Protein E7 Type Introduction
  2. 4.1.1 CUE-201
  3. 4.1.2 CerviVax
  4. 4.1.3 CUE-101
  5. 4.1.4 BLSILSB-710c
  6. 4.1.5 Others
  7. 4.2 Global Human Papillomavirus Protein E7 Sales Volume by Type
  8. 4.2.1 Global Human Papillomavirus Protein E7 Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Human Papillomavirus Protein E7 Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Human Papillomavirus Protein E7 Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Human Papillomavirus Protein E7 Sales Value by Type
  12. 4.3.1 Global Human Papillomavirus Protein E7 Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Human Papillomavirus Protein E7 Sales Value by Type (2021-2032)
  14. 4.3.3 Global Human Papillomavirus Protein E7 Sales Value Share by Type (2021-2032)
5 Human Papillomavirus Protein E7 Market by Application
  1. 5.1 Human Papillomavirus Protein E7 Application Introduction
  2. 5.1.1 Rectal Cancer
  3. 5.1.2 Penile Cancer
  4. 5.1.3 Anal Cancer
  5. 5.1.4 Lung Cancer
  6. 5.1.5 Others
  7. 5.2 Global Human Papillomavirus Protein E7 Sales Volume by Application
  8. 5.2.1 Global Human Papillomavirus Protein E7 Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Human Papillomavirus Protein E7 Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Human Papillomavirus Protein E7 Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Human Papillomavirus Protein E7 Sales Value by Application
  12. 5.3.1 Global Human Papillomavirus Protein E7 Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Human Papillomavirus Protein E7 Sales Value by Application (2021-2032)
  14. 5.3.3 Global Human Papillomavirus Protein E7 Sales Value Share by Application (2021-2032)
6 Human Papillomavirus Protein E7 Regional Sales and Value Analysis
  1. 6.1 Global Human Papillomavirus Protein E7 Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Papillomavirus Protein E7 Sales by Region (2021-2032)
  3. 6.2.1 Global Human Papillomavirus Protein E7 Sales by Region: 2021-2026
  4. 6.2.2 Global Human Papillomavirus Protein E7 Sales by Region (2027-2032)
  5. 6.3 Global Human Papillomavirus Protein E7 Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Human Papillomavirus Protein E7 Sales Value by Region (2021-2032)
  7. 6.4.1 Global Human Papillomavirus Protein E7 Sales Value by Region: 2021-2026
  8. 6.4.2 Global Human Papillomavirus Protein E7 Sales Value by Region (2027-2032)
  9. 6.5 Global Human Papillomavirus Protein E7 Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Human Papillomavirus Protein E7 Sales Value (2021-2032)
  12. 6.6.2 North America Human Papillomavirus Protein E7 Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Human Papillomavirus Protein E7 Sales Value (2021-2032)
  15. 6.7.2 Europe Human Papillomavirus Protein E7 Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Human Papillomavirus Protein E7 Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Human Papillomavirus Protein E7 Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Human Papillomavirus Protein E7 Sales Value (2021-2032)
  21. 6.9.2 South America Human Papillomavirus Protein E7 Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Human Papillomavirus Protein E7 Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Human Papillomavirus Protein E7 Sales Value Share by Country, 2025 VS 2032
7 Human Papillomavirus Protein E7 Country-level Sales and Value Analysis
  1. 7.1 Global Human Papillomavirus Protein E7 Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Human Papillomavirus Protein E7 Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Human Papillomavirus Protein E7 Sales by Country (2021-2032)
  4. 7.3.1 Global Human Papillomavirus Protein E7 Sales by Country (2021-2026)
  5. 7.3.2 Global Human Papillomavirus Protein E7 Sales by Country (2027-2032)
  6. 7.4 Global Human Papillomavirus Protein E7 Sales Value by Country (2021-2032)
  7. 7.4.1 Global Human Papillomavirus Protein E7 Sales Value by Country (2021-2026)
  8. 7.4.2 Global Human Papillomavirus Protein E7 Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Human Papillomavirus Protein E7 Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Human Papillomavirus Protein E7 Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Human Papillomavirus Protein E7 Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 VLPbio
  2. 8.1.1 VLPbio Company Information
  3. 8.1.2 VLPbio Business Overview
  4. 8.1.3 VLPbio Human Papillomavirus Protein E7 Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 VLPbio Human Papillomavirus Protein E7 Product Portfolio
  6. 8.1.5 VLPbio Recent Developments
  7. 8.2 Transgene SA
  8. 8.2.1 Transgene SA Company Information
  9. 8.2.2 Transgene SA Business Overview
  10. 8.2.3 Transgene SA Human Papillomavirus Protein E7 Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Transgene SA Human Papillomavirus Protein E7 Product Portfolio
  12. 8.2.5 Transgene SA Recent Developments
  13. 8.3 Touchlight Genetics Ltd
  14. 8.3.1 Touchlight Genetics Ltd Company Information
  15. 8.3.2 Touchlight Genetics Ltd Business Overview
  16. 8.3.3 Touchlight Genetics Ltd Human Papillomavirus Protein E7 Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Touchlight Genetics Ltd Human Papillomavirus Protein E7 Product Portfolio
  18. 8.3.5 Touchlight Genetics Ltd Recent Developments
  19. 8.4 Selecta Biosciences Inc
  20. 8.4.1 Selecta Biosciences Inc Company Information
  21. 8.4.2 Selecta Biosciences Inc Business Overview
  22. 8.4.3 Selecta Biosciences Inc Human Papillomavirus Protein E7 Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Selecta Biosciences Inc Human Papillomavirus Protein E7 Product Portfolio
  24. 8.4.5 Selecta Biosciences Inc Recent Developments
  25. 8.5 MedImmune LLC
  26. 8.5.1 MedImmune LLC Company Information
  27. 8.5.2 MedImmune LLC Business Overview
  28. 8.5.3 MedImmune LLC Human Papillomavirus Protein E7 Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 MedImmune LLC Human Papillomavirus Protein E7 Product Portfolio
  30. 8.5.5 MedImmune LLC Recent Developments
  31. 8.6 Inovio Pharmaceuticals Inc
  32. 8.6.1 Inovio Pharmaceuticals Inc Company Information
  33. 8.6.2 Inovio Pharmaceuticals Inc Business Overview
  34. 8.6.3 Inovio Pharmaceuticals Inc Human Papillomavirus Protein E7 Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Inovio Pharmaceuticals Inc Human Papillomavirus Protein E7 Product Portfolio
  36. 8.6.5 Inovio Pharmaceuticals Inc Recent Developments
  37. 8.7 Immunovaccine Inc
  38. 8.7.1 Immunovaccine Inc Company Information
  39. 8.7.2 Immunovaccine Inc Business Overview
  40. 8.7.3 Immunovaccine Inc Human Papillomavirus Protein E7 Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Immunovaccine Inc Human Papillomavirus Protein E7 Product Portfolio
  42. 8.7.5 Immunovaccine Inc Recent Developments
  43. 8.8 iBio Inc
  44. 8.8.1 iBio Inc Company Information
  45. 8.8.2 iBio Inc Business Overview
  46. 8.8.3 iBio Inc Human Papillomavirus Protein E7 Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 iBio Inc Human Papillomavirus Protein E7 Product Portfolio
  48. 8.8.5 iBio Inc Recent Developments
  49. 8.9 Hookipa Biotech AG
  50. 8.9.1 Hookipa Biotech AG Company Information
  51. 8.9.2 Hookipa Biotech AG Business Overview
  52. 8.9.3 Hookipa Biotech AG Human Papillomavirus Protein E7 Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Hookipa Biotech AG Human Papillomavirus Protein E7 Product Portfolio
  54. 8.9.5 Hookipa Biotech AG Recent Developments
  55. 8.10 Genexine Inc
  56. 8.10.1 Genexine Inc Company Information
  57. 8.10.2 Genexine Inc Business Overview
  58. 8.10.3 Genexine Inc Human Papillomavirus Protein E7 Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Genexine Inc Human Papillomavirus Protein E7 Product Portfolio
  60. 8.10.5 Genexine Inc Recent Developments
  61. 8.11 Formune SL
  62. 8.11.1 Formune SL Company Information
  63. 8.11.2 Formune SL Business Overview
  64. 8.11.3 Formune SL Human Papillomavirus Protein E7 Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Formune SL Human Papillomavirus Protein E7 Product Portfolio
  66. 8.11.5 Formune SL Recent Developments
  67. 8.12 Etubics Corp
  68. 8.12.1 Etubics Corp Company Information
  69. 8.12.2 Etubics Corp Business Overview
  70. 8.12.3 Etubics Corp Human Papillomavirus Protein E7 Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Etubics Corp Human Papillomavirus Protein E7 Product Portfolio
  72. 8.12.5 Etubics Corp Recent Developments
  73. 8.13 Cancer Research Technology Ltd
  74. 8.13.1 Cancer Research Technology Ltd Company Information
  75. 8.13.2 Cancer Research Technology Ltd Business Overview
  76. 8.13.3 Cancer Research Technology Ltd Human Papillomavirus Protein E7 Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Cancer Research Technology Ltd Human Papillomavirus Protein E7 Product Portfolio
  78. 8.13.5 Cancer Research Technology Ltd Recent Developments
  79. 8.14 BioNTech AG
  80. 8.14.1 BioNTech AG Company Information
  81. 8.14.2 BioNTech AG Business Overview
  82. 8.14.3 BioNTech AG Human Papillomavirus Protein E7 Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 BioNTech AG Human Papillomavirus Protein E7 Product Portfolio
  84. 8.14.5 BioNTech AG Recent Developments
  85. 8.15 Bioleaders Corp
  86. 8.15.1 Bioleaders Corp Company Information
  87. 8.15.2 Bioleaders Corp Business Overview
  88. 8.15.3 Bioleaders Corp Human Papillomavirus Protein E7 Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Bioleaders Corp Human Papillomavirus Protein E7 Product Portfolio
  90. 8.15.5 Bioleaders Corp Recent Developments
  91. 8.16 Advaxis Inc
  92. 8.16.1 Advaxis Inc Company Information
  93. 8.16.2 Advaxis Inc Business Overview
  94. 8.16.3 Advaxis Inc Human Papillomavirus Protein E7 Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Advaxis Inc Human Papillomavirus Protein E7 Product Portfolio
  96. 8.16.5 Advaxis Inc Recent Developments
  97. 8.17 Abion Inc
  98. 8.17.1 Abion Inc Company Information
  99. 8.17.2 Abion Inc Business Overview
  100. 8.17.3 Abion Inc Human Papillomavirus Protein E7 Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Abion Inc Human Papillomavirus Protein E7 Product Portfolio
  102. 8.17.5 Abion Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Human Papillomavirus Protein E7 Value Chain Analysis
  2. 9.1.1 Human Papillomavirus Protein E7 Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Human Papillomavirus Protein E7 Sales Mode & Process
  6. 9.2 Human Papillomavirus Protein E7 Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Human Papillomavirus Protein E7 Distributors
  9. 9.2.3 Human Papillomavirus Protein E7 Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst